Displaying One Session

Time
10:30 - 12:00

Welcome and Introductions (ID 5004)

Immunotherapy in NSCLC – Where Are We in 2021? (ID 5005)

Why Do We Need Another PD-1 Inhibitor? (ID 5006)

Tislelizumab: The Backbone of Future Immunotherapy Combinations (ID 5008)

What Comes Next? TIGIT, TIM3, OX40 Combinations (ID 5010)

Concluding Remarks (ID 5011)